Cholinesterase inhibitors for Alzheimer's disease: Multitargeting strategy based on anti-Alzheimer's drugs repositioning
dc.creator | Kabir M.T. | |
dc.creator | Uddin M.S. | |
dc.creator | Begum M.M. | |
dc.creator | Thangapandiyan S. | |
dc.creator | Rahman M.S. | |
dc.creator | Aleya L. | |
dc.creator | Mathew B. | |
dc.creator | Ahmed M. | |
dc.creator | Barreto G.E. | |
dc.creator | Ashraf G.M. | |
dc.date.accessioned | 2020-09-02T22:21:03Z | |
dc.date.accessioned | 2022-11-08T20:27:55Z | |
dc.date.available | 2020-09-02T22:21:03Z | |
dc.date.available | 2022-11-08T20:27:55Z | |
dc.date.created | 2020-09-02T22:21:03Z | |
dc.date.issued | 2019 | |
dc.identifier | 25, 33, 3519-3535 | |
dc.identifier | 13816128 | |
dc.identifier | https://hdl.handle.net/20.500.12728/4990 | |
dc.identifier.uri | https://repositorioslatinoamericanos.uchile.cl/handle/2250/5146630 | |
dc.language | en | |
dc.publisher | Bentham Science Publishers | |
dc.subject | Acetylcholine | |
dc.subject | Acetylcholinesterase inhibitors | |
dc.subject | Alzheimer's disease | |
dc.subject | Donepezil | |
dc.subject | Galantamine | |
dc.subject | Rivastigmine | |
dc.subject | Tacrine | |
dc.subject | cholinesterase inhibitor | |
dc.subject | donepezil | |
dc.subject | donepezil derivative | |
dc.subject | galantamine | |
dc.subject | galantamine derivative | |
dc.subject | memantine | |
dc.subject | placebo | |
dc.subject | rivastigmine | |
dc.subject | rivastigmine derivative | |
dc.subject | tacrine | |
dc.subject | tacrine derivative | |
dc.subject | theophylline | |
dc.subject | unclassified drug | |
dc.subject | cholinesterase inhibitor | |
dc.subject | donepezil | |
dc.subject | galantamine | |
dc.subject | rivastigmine | |
dc.subject | tacrine | |
dc.subject | abdominal cramp | |
dc.subject | abdominal pain | |
dc.subject | age | |
dc.subject | Alzheimer disease | |
dc.subject | anorexia | |
dc.subject | cholinergic system | |
dc.subject | diarrhea | |
dc.subject | dizziness | |
dc.subject | drug absorption | |
dc.subject | drug blood level | |
dc.subject | drug efficacy | |
dc.subject | drug elimination | |
dc.subject | drug half life | |
dc.subject | drug mechanism | |
dc.subject | drug structure | |
dc.subject | dyspepsia | |
dc.subject | faintness | |
dc.subject | fatigue | |
dc.subject | human | |
dc.subject | hypertransaminasemia | |
dc.subject | insomnia | |
dc.subject | liver toxicity | |
dc.subject | muscle cramp | |
dc.subject | nausea | |
dc.subject | neurofibrillary tangle | |
dc.subject | plasma clearance | |
dc.subject | priority journal | |
dc.subject | Review | |
dc.subject | time to maximum plasma concentration | |
dc.subject | vomiting | |
dc.subject | drug repositioning | |
dc.subject | Alzheimer Disease | |
dc.subject | Cholinesterase Inhibitors | |
dc.subject | Donepezil | |
dc.subject | Drug Repositioning | |
dc.subject | Galantamine | |
dc.subject | Humans | |
dc.subject | Rivastigmine | |
dc.subject | Tacrine | |
dc.title | Cholinesterase inhibitors for Alzheimer's disease: Multitargeting strategy based on anti-Alzheimer's drugs repositioning | |
dc.type | Review |